Online inquiry

IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5573MR)

This product GTTS-WQ5573MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD33 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001082618.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 945
UniProt ID P20138
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5573MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15784MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ13732MR IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA RC48-0
GTTS-WQ6755MR IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DS-1062
GTTS-WQ8617MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA HuM195
GTTS-WQ13136MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-04360365
GTTS-WQ14431MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RO 24-7375
GTTS-WQ8635MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ13957MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN3470-3471-3479
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW